Whats going on here?

EvolutionaryScale, an AI startup revolutionizing biology, just raised an impressive $142 million in seed funding.

What does this mean?

The funding round, led by industry stalwarts Nat Friedman, Daniel Gross, and Lux Capital, also secured significant backing from AWS and NVIDIAs venture arm. Josh Wolfe from Lux described this milestone as a 'ChatGPT moment for biology.' EvolutionaryScale's groundbreaking large language model, ESM3, aims to transform drug discovery and environmental engineering. Some models will be open-sourced for non-commercial research, while AWS and NVIDIA will support commercial use. EvolutionaryScale's innovative AI has already engineered a novel fluorescent protein, achieving evolutionary advancements that would have taken nature 500 million years.

Why should I care?

For markets: Pioneering the future of biotech.

This substantial investment signals strong confidence in AI's potential to revolutionize biotech. With major players like AWS and NVIDIA backing EvolutionaryScale, investors should watch how these technologies might drive significant growth in the biotech sector.

The bigger picture: AI, biology, and the next frontier.

AI's integration into biology is not just advancing drug discovery but also poised to address environmental challenges, like engineering microbes to break down plastic. However, this progress comes with caution, as generative AI's dual-use potential raises concerns about the creation of bioweapons.

Excerpt from:

EvolutionaryScale Raises $142 Million To Transform Biology With AI - Finimize